Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Gold Prices Hold Near $4,400 as Fed Rate Hike Bets Ease 
JPMorgan Sees ECB Raising Rates to 2.75% in December 
OPEC+ Expected to Hold October Oil Output Steady 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Dollar Hits Two-Week High as Iran Conflict Lifts Oil and Bond Yields 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Gold Prices Hold Near $4,500 as Fed Rate Hike Bets Ease 
Chinese AI Stocks Rally After OpenAI Launches GPT-6 Astra 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
Celltrion biopharmaceutical company based in Incheon, South Korea, has become the largest shareholder in United Kingdom’s Iksuda Therapeutics biotech firm. This happened after the former acquired more stake in the antibody-drug conjugates (ADCs) developer’s company.
According to The Korea Herald, Celltrion now owns a 47.05% stake in Iksuda Therapeutics. It was able to buy more shares after securing a new growth fund. The South Korean leading drugmaker announced its latest acquisition on Wednesday, Jan. 25.
Celltrion shared it paid for the asset through direct investment and a fund it set up with Mirae Asset Capital. With the deal, Celltrion and the Mirae Asset Celltrion New Growth Fund are now the largest co-shareholders of Iksuda Therapeutics. The initial share that Celltrion owned prior to the new investment is unknown, as the company reportedly declined to say.
Moreover, the investment was made under the same contract terms that Celltrion and Mirae Asset Capital signed before. In the deal, they agreed to invest a total of KRW58 billion or about $47 million when they participated in the British biotech firm’s Series A financing round that took place in June 2021, as per The Korea Economic Daily.
With its increased share in Iksuda Therapeutics, Celltrion now expects to transform and expand its anti-cancer treatments by using the latter’s ADC technology for its biosimilar products - Herzuma and Truxima.
“We are working with and investing in various biotechnologies with promising platforms. We will be taking versatile measures to increase our influence in the growing ADC field,” the company said in a statement.
Iksuda Therapeutics mainly works on the development of the next-generation ADC for incurable cancer drugs. This is an anti-cancer tech that has been receiving a lot of attention recently because it was able to specifically attack cancer cells by simply connecting antibody drugs and chemical anti-cancer medicines.
